Dose prescription in SBRT for early-stage non-small cell lung cancer: are we all speaking the same language?

To identify the dose-prescription modality that better correlates with oncologic outcomes, future studies should guarantee a close uniformity of dose distribution between cases and complete dose parameters reporting for treatment volumes and OARs.